Optimal use of SGLT2 inhibitors in diabetic kidney transplant recipients
Sodium-glucose cotransporter 2 inhibitor (SGLT2i), a glucosuric agent initially approved for use as an antidiabetic agent, was unexpectedly found to confer cardio-and reno-protective effects in individuals with or without type 2 diabetes mellitus. Despite mounting evidence suggesting that SGLT2i pro...
Saved in:
| Published in: | Frontiers in Nephrology (Online) Vol. 2; p. 1014241 |
|---|---|
| Main Authors: | , |
| Format: | Journal Article |
| Language: | English |
| Published: |
Switzerland
Frontiers Media S.A
10-11-2022
|
| Subjects: | |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Sodium-glucose cotransporter 2 inhibitor (SGLT2i), a glucosuric agent initially approved for use as an antidiabetic agent, was unexpectedly found to confer cardio-and reno-protective effects in individuals with or without type 2 diabetes mellitus. Despite mounting evidence suggesting that SGLT2i provides cardio- and reno-protective benefits in both diabetic and non-diabetic and in chronic kidney disease (CKD) patients in the general population, reservations for its use in the transplant setting persist due to concerns for increased risk of genital mycotic and urinary tract infections. A comprehensive review of the literature on the efficacy and safety of SGLT2i use in diabetic kidney transplant recipients is herein presented followed by authors' opinion on its optimal use in this patient population. |
|---|---|
| Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 Reviewed by: Ayman Al Jurdi, Massachusetts General Hospital, Harvard Medical School, United States; Chi Yuen Simon Cheung, Queen Elizabeth Hospital (QEH), Hong Kong SAR, China Edited by: Masoud Sadeghi, Kermanshah University of Medical Sciences, Iran This article was submitted to Kidney Transplantation, a section of the journal Frontiers in Nephrology |
| ISSN: | 2813-0626 2813-0626 |
| DOI: | 10.3389/fneph.2022.1014241 |